We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+10.28%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$321M
AUM Growth
+$15K
(+0%)
Cap. Flow
-$22.8M
Cap. Flow
% of AUM
-7.1%
Top 10 Holdings %
Top 10 Hldgs %
88.4%
Holding
16
New
2
Increased
3
Reduced
11
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
McKesson
MCK
|
+$18.7M |
| 2 |
Amgen
AMGN
|
+$15.5M |
| 3 |
JNP
Juniper Pharmaceuticals, Inc. Common Stock
JNP
|
+$958K |
| 4 |
STRR
Star Equity Holdings
STRR
|
+$48.2K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
|
+$18.8M |
| 2 |
Merck
MRK
|
+$13M |
| 3 |
Orthofix Medical
OFIX
|
+$8.44M |
| 4 |
Enanta Pharmaceuticals
ENTA
|
+$7.36M |
| 5 |
United Therapeutics
UTHR
|
+$6.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Enanta Pharmaceuticals
ENTA
$366M
| $50.9M | 15.85% |
866,770
-147,077
| -15% | -$7.36M |
|
|
2
United Therapeutics
UTHR
$25.8B
| $43.6M | 13.58% |
294,429
-52,082
| -15% | -$6.62M |
|
3
Gilead Sciences
GILD
$162B
| $34.2M | 10.68% |
478,053
-42,871
| -8% | -$3.26M |
|
|
SCMP
4
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
| $23.4M | 7.3% |
1,304,376
-1,529,040
| -54% | -$18.8M |
|
|
5
McKesson
MCK
$100B
| $19.7M | 6.15% |
+126,482
| New | +$18.7M |
|
|
IVC
6
DELISTED
Invacare Corporation
IVC
| $18.7M | 5.82% |
1,107,770
-16,758
| -1% | -$273K |
|
|
AVNS
7
DELISTED
Avanos Medical
AVNS
| $18.2M | 5.69% |
395,015
-83,606
| -17% | -$3.84M |
|
|
SRGA
8
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $17.8M | 5.54% |
144,495
-2,632
| -2% | -$361K |
|
|
9
Orthofix Medical
OFIX
$477M
| $17.7M | 5.53% |
324,357
-162,744
| -33% | -$8.44M |
|
|
10
Amgen
AMGN
$208B
| $15.2M | 4.74% |
+87,477
| New | +$15.5M |
|
|
11
Merck
MRK
$322B
| $8.97M | 2.8% |
167,120
-234,909
| -58% | -$13M |
|
12
CONMED
CNMD
$1.39B
| $8.39M | 2.61% |
164,547
-27,054
| -14% | -$1.41M |
|
|
JNP
13
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
| $2.13M | 0.67% |
440,102
+196,974
| +81% | +$958K |
|
|
VXRT
14
DELISTED
Vaxart
VXRT
| $1.59M | 0.5% |
255,412
-2,436
| -0.9% | -$17K |
|
|
STRR
15
DELISTED
Star Equity Holdings
STRR
| $912K | 0.28% |
7,084
+400
| +6% | +$48.2K |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q4 2017 Portfolio in Review
As of Q4 2017, Krensavage Asset Management held 16 positions worth $321M, up 0% from $321M the previous quarter. Its ten largest holdings account for 88% of the portfolio.
Krensavage Asset Management withdrew a net $22.8M in Q4 2017, reducing 11 holdings. Its largest reduction was Sucampo Pharmaceuticals, Inc., cutting an estimated $18.8M.
By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 73% a quarter earlier.
Against the trend, Krensavage Asset Management opened a new position in McKesson worth $19.7M.
- Krensavage Asset Management's largest Q4 2017 buy was McKesson: 126,482 shares worth $19.7M.
- Krensavage Asset Management added most to Juniper Pharmaceuticals, Inc. Common Stock in Q4 2017, an estimated $958K increase.
- Krensavage Asset Management's biggest Q4 2017 reduction was Sucampo Pharmaceuticals, Inc., cutting an estimated $18.8M.
- Krensavage Asset Management's ten largest holdings make up 88% of its $321M portfolio in Q4 2017.
- Krensavage Asset Management opened 2 new positions and closed 0 in Q4 2017.
- Krensavage Asset Management's portfolio value rose 0% quarter-over-quarter to $321M.
Based on Krensavage Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.